These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35109913)

  • 1. Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease.
    van Kooten HA; Ditters IAM; Hoogeveen-Westerveld M; Jacobs EH; van den Hout JMP; van Doorn PA; Pijnappel WWMP; van der Ploeg AT; van der Beek NAME
    Orphanet J Rare Dis; 2022 Feb; 17(1):31. PubMed ID: 35109913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report.
    Castellar-Leones SM; Ortiz-Corredor F; Manrique-Hernández D; Sánchez-Peñarete D; Ruiz-Ospina E; Soto-Peña D; Correa-Arrieta C
    J Med Case Rep; 2024 Jul; 18(1):328. PubMed ID: 39020349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
    Filosto M; Cotti Piccinelli S; Ravaglia S; Servidei S; Moggio M; Musumeci O; Donati MA; Pegoraro E; Di Muzio A; Maggi L; Tonin P; Marrosu G; Sancricca C; Lerario A; Sacchini M; Semplicini C; Bozzoni V; Telese R; Bonanno S; Piras R; Maioli MA; Ricci G; Vercelli L; Galvagni A; Gallo Cassarino S; Caria F; Mongini T; Siciliano G; Padovani A; Toscano A
    Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.
    de Vries JM; Kuperus E; Hoogeveen-Westerveld M; Kroos MA; Wens SC; Stok M; van der Beek NA; Kruijshaar ME; Rizopoulos D; van Doorn PA; van der Ploeg AT; Pijnappel WW
    Genet Med; 2017 Jan; 19(1):90-97. PubMed ID: 27362911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review.
    Ditters IAM; van Kooten HA; van der Beek NAME; van der Ploeg AT; Huidekoper HH; van den Hout JMP
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
    Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
    Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
    Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
    Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease.
    Winkler M; von Landenberg C; Kuchenbecker K; Reimann J; Kornblum C
    Neuromuscul Disord; 2022 Mar; 32(3):195-205. PubMed ID: 35120758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
    Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
    Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive immunotherapy combined with bortezomib and rituximab for membranous nephropathy associated with enzyme replacement therapy in Pompe disease.
    Sasaki K; Uchimura T; Inaba A; Otani M; Hanakawa J; Ito S
    Pediatr Nephrol; 2023 Mar; 38(3):921-925. PubMed ID: 35864224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
    Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
    Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients.
    Poelman E; van den Dorpel JJA; Hoogeveen-Westerveld M; van den Hout JMP; van der Giessen LJ; van der Beek NAME; Pijnappel WWMP; van der Ploeg AT
    J Inherit Metab Dis; 2020 Nov; 43(6):1243-1253. PubMed ID: 32506446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy.
    Poelman E; Hoogeveen-Westerveld M; Kroos-de Haan MA; van den Hout JMP; Bronsema KJ; van de Merbel NC; van der Ploeg AT; Pijnappel WWMP
    J Pediatr; 2018 Apr; 195():236-243.e3. PubMed ID: 29428273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
    Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
    Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
    Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy.
    Desai AK; Kazi ZB; Bali DS; Kishnani PS
    Mol Genet Metab Rep; 2019 Sep; 20():100475. PubMed ID: 31193175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
    Messinger YH; Mendelsohn NJ; Rhead W; Dimmock D; Hershkovitz E; Champion M; Jones SA; Olson R; White A; Wells C; Bali D; Case LE; Young SP; Rosenberg AS; Kishnani PS
    Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation.
    Desai AK; Shrivastava G; Grant CL; Wang RY; Burt TD; Kishnani PS
    Front Immunol; 2024; 15():1360369. PubMed ID: 38524130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.